{"gene":"ABCD1","run_date":"2026-06-09T22:02:36","timeline":{"discoveries":[{"year":1993,"finding":"Positional cloning identified the ALD gene, whose predicted protein (ALDP) shows significant homology to the 70-kDa peroxisomal membrane protein (PMP70) involved in peroxisome biogenesis and belongs to the ATP-binding cassette superfamily, suggesting it encodes a putative peroxisomal transporter involved in import or anchoring of VLCFA-CoA synthetase.","method":"Positional cloning; sequence homology analysis","journal":"Biochimie","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — positional cloning with functional inference; single study but gene identification confirmed by multiple subsequent labs","pmids":["8507690"],"is_preprint":false},{"year":1994,"finding":"ALDP is a peroxisomal membrane protein: monoclonal antibodies detected a 75 kDa band absent in ALD patients, and immunofluorescence/immunoelectron microscopy localized ALDP to the peroxisomal membrane. Distinct immunofluorescence patterns were observed in Zellweger syndrome cell lines.","method":"Monoclonal antibody generation; immunofluorescence; immunoelectron microscopy; Western blot","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct subcellular localization by immunofluorescence and immunoelectron microscopy, replicated across multiple cell lines and confirmed in patient cells","pmids":["8004093"],"is_preprint":false},{"year":1995,"finding":"ALDP subcellular distribution and abundance examined in ALD patient fibroblasts: 69% of patients lacked punctate peroxisomal immunoreactivity; missense mutations could affect ALDP stability or localization; carboxy-terminal region has a function in stabilizing ALDP. No correlation between immunofluorescence pattern and clinical phenotype was found.","method":"Indirect immunofluorescence; mutation analysis in patient fibroblasts","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiments in patient-derived cells with mutation analysis; single lab but multiple patient samples","pmids":["7668254"],"is_preprint":false},{"year":1996,"finding":"Analysis of 44 ALD kindreds showed that >50% of missense mutations led to complete absence of ALDP immunoreactivity, indicating mutations destabilize the protein; mutations concentrated in/near putative transmembrane segments 2–5, EAA-like motif, and ATP-binding domain. In heterozygous carriers from ALDP-negative kindreds, a mosaic pattern of ALDP-positive and -negative cells was confirmed by X-inactivation.","method":"SSCP/denaturing gradient gel electrophoresis; immunocytofluorescence; Western blot of fibroblasts and white blood cells","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — immunofluorescence and Western blot in patient cells with mutation mapping; single lab, multiple patients","pmids":["8651290"],"is_preprint":false},{"year":1996,"finding":"Absence of truncated ALDP proteins in patients with nonsense/frameshift mutations in the carboxy terminus indicates the carboxy terminus is required for ALDP protein stability.","method":"Western blot; mutation analysis in patient fibroblasts","journal":"Journal of inherited metabolic disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Western blot in patient-derived fibroblasts correlated with mutation type; single lab","pmids":["8892025"],"is_preprint":false},{"year":1998,"finding":"4-Phenylbutyrate treatment of X-ALD patient cells and knockout mouse cells increased expression of the closely related peroxisomal protein ALDRP (ABCD2), decreased VLCFA levels, and increased VLCFA beta-oxidation. ALDRP cDNA complementation of X-ALD fibroblasts corrected the biochemical defect, demonstrating functional redundancy between ALDP and ALDRP.","method":"cDNA complementation in X-ALD fibroblasts; VLCFA beta-oxidation assay; ALDRP expression analysis; dietary treatment of X-ALD knockout mice","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — complementation assay with functional beta-oxidation readout in patient cells, plus in vivo mouse data; multiple orthogonal methods","pmids":["9809549"],"is_preprint":false},{"year":1999,"finding":"ALDP forms homodimers with itself and heterodimers with other peroxisomal ABC proteins (ALDRP, PMP70). cDNA complementation studies suggest overlapping functions among peroxisomal ABC proteins. There are at least two peroxisomal VLCFA-CoA synthetase (VLCS) activities, one ALDP-dependent and one ALDP-independent.","method":"Protein dimerization assays (in vitro); cDNA complementation; VLCS activity assays","journal":"Neurochemical research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro dimerization and functional complementation; single lab","pmids":["10227685"],"is_preprint":false},{"year":1999,"finding":"Overexpression of ALDRP (ABCD2) in X-ALD patient fibroblasts restored impaired peroxisomal beta-oxidation and prevented VLCFA accumulation, functionally replacing ALDP. Dietary fenofibrate treatment of ALDP-deficient mice stimulated ALDRP and PMP70 expression and corrected the peroxisomal beta-oxidation defect in liver.","method":"Transient and stable cDNA overexpression in X-ALD fibroblasts; peroxisomal beta-oxidation assay; VLCFA measurement; dietary treatment of knockout mice; immunofluorescence","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — functional restoration by complementation in patient cells confirmed by beta-oxidation assay and VLCFA measurement, plus in vivo mouse confirmation","pmids":["10196381"],"is_preprint":false},{"year":1999,"finding":"ALDP expression level is a fundamental determinant of peroxisomal VLCFA beta-oxidation: ALDP overexpression alone restored peroxisomal VLCFA beta-oxidation in SV40T-transformed cells where both acyl-CoA oxidase and ALDP were reduced, demonstrating ALDP acts as a 'gatekeeper' for VLCFA homeostasis.","method":"ALDP overexpression in SV40T-transformed cells; peroxisomal beta-oxidation assay; Western blot","journal":"Molecular genetics and metabolism","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro functional assay with overexpression rescue; single lab","pmids":["10068511"],"is_preprint":false},{"year":2002,"finding":"ALDP (and PMP70/ABCD3) bind and hydrolyze ATP: photoaffinity labeling of rat liver peroxisomes showed both proteins bind 8-azido-ATP; Mg2+ promoted ATP hydrolysis to ADP with subsequent ADP dissociation. Both ALDP and PMP70 were also phosphorylated at tyrosine residue(s). Vanadate-induced nucleotide trapping was not observed.","method":"Photoaffinity labeling with 8-azido-[α-32P]ATP and 8-azido-[γ-32P]ATP; co-immunoprecipitation; in vitro ATPase assay using rat liver peroxisomes","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct biochemical demonstration of ATP binding and hydrolysis by ALDP in native peroxisomes with multiple nucleotide analogs and Mg2+ dependency","pmids":["12176987"],"is_preprint":false},{"year":2004,"finding":"In vivo genetic epistasis in ALD-knockout mice: overexpression of ALDRP (ABCD2) prevented both VLCFA accumulation and neurodegenerative features in ALD(-/-) mice. Double knockout (ALD/ALDRP) mice showed earlier onset and more severe disease including inflammatory features compared to ALD single mutants. This demonstrates functional redundancy/overlap between ABCD1 and ABCD2 in vivo.","method":"Transgenic mouse overexpression; double knockout mouse model; VLCFA measurement; histopathology; behavioral analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with rescue and synthetic severity phenotypes in vivo, replicated across multiple mouse lines","pmids":["15489218"],"is_preprint":false},{"year":2004,"finding":"Mouse liver ALDP and PMP70 predominantly form homomeric complexes in vivo: two-step purification and preparative immunoprecipitation of mouse liver peroxisomes showed no evidence of ALDP/PMP70 heterodimers or accessory proteins under normal expression conditions.","method":"Protein complex purification from mouse liver peroxisomes; preparative immunoprecipitation; biochemical characterization","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical purification from native tissue; single lab; contradicts some in vitro studies","pmids":["15276650"],"is_preprint":false},{"year":2007,"finding":"ALDP forms homodimers and ALDP/PMP70 heterodimers in living cells as demonstrated by FRET microscopy. ALDP homodimers predominate. The last 87 C-terminal amino acids are the most important domain mediating these interactions, and the N-terminal transmembrane region provides additional stabilization of ALDP homodimers.","method":"Live-cell FRET microscopy; C-terminal deletion constructs; yeast two-hybrid; immunoprecipitation; statistical analysis (PDSA and KS tests)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vivo FRET in intact living cells with domain-deletion mutagenesis; multiple orthogonal methods; rigorous statistical validation","pmids":["17609205"],"is_preprint":false},{"year":2007,"finding":"Missense mutations in the C-terminal half of ALDP (S606L, R617H, H667D) cause rapid proteasomal degradation; a proteasome inhibitor restored mutant ALDP expression. Wild-type ALDP co-expressed with H667D mutant also disappeared, suggesting dominant-negative degradation after dimerization. The region between transmembrane domains 2 and 3 (e.g., Y174C mutation) is required for peroxisomal targeting of ALDP.","method":"Expression of mutant ALDP in X-ALD fibroblasts and CHO cells; proteasome inhibitor treatment; immunofluorescence; Western blot","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — proteasome inhibitor rescue of mutant protein, dominant-negative co-degradation, and localization mutant; multiple orthogonal methods in single study","pmids":["17542813"],"is_preprint":false},{"year":2008,"finding":"siRNA-mediated silencing of Abcd1 (and Abcd2) in mouse primary astrocytes caused VLCFA accumulation and triggered an inflammatory response involving NF-κB, AP-1, and C/EBP transcription factors, including induction of iNOS and inflammatory cytokines. Correction of the metabolic defect with monoenoic fatty acids reduced the inflammatory response, directly linking VLCFA accumulation to inflammation.","method":"siRNA knockdown in primary mouse astrocytes; VLCFA measurement; inflammatory gene expression; transcription factor analysis; monoenoic fatty acid rescue","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with specific inflammatory phenotype and metabolic rescue; single lab, in vitro","pmids":["18723473"],"is_preprint":false},{"year":2011,"finding":"ALDRP (ABCD2) and ALDP (ABCD1) physically interact: proximity ligation assay and co-immunoprecipitation demonstrated a direct protein-protein interaction between ALDRP and ALDP. Inactive ALDRP-EGFP exerted a trans-dominant-negative effect on ALDP function, reducing beta-oxidation of C26:0 and C24:0. ALDRP overexpression reduces saturated VLCFA (redundant with ALDP) and specifically promotes DHA (C22:6n-3) metabolism.","method":"Proximity ligation assay; co-immunoprecipitation; inducible expression of wild-type and mutant ALDRP-EGFP; fatty acid content analysis in phospholipids; beta-oxidation assays for C26:0, C24:0, and DHA","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — physical interaction confirmed by two orthogonal methods (PLA and Co-IP); functional consequence demonstrated by dominant-negative and dose-dependent beta-oxidation assays","pmids":["21209459"],"is_preprint":false},{"year":2015,"finding":"ABCD1 deficiency in brain endothelial cells (via siRNA silencing) caused upregulation of adhesion molecules (ICAM1) and downregulation of tight junction proteins (CLDN5) before VLCFA accumulation, mediated through downregulation of the transcription factor c-MYC. MYC silencing mimicked the effects of ABCD1 silencing on CLDN5 and ICAM1 without affecting ABCD1 protein levels, placing c-MYC downstream of ABCD1 but upstream of endothelial barrier function.","method":"siRNA silencing of ABCD1 in human brain microvascular endothelial cells; PCR array; Western blot; MYC silencing; monocyte adhesion and transmigration assays","journal":"Brain : a journal of neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established by MYC knockdown mimicking ABCD1 knockdown phenotype; single lab, in vitro","pmids":["26377633"],"is_preprint":false},{"year":2015,"finding":"ABCD1 silencing in oligodendrocyte (B12) and astrocyte (U87) cells caused mitochondrial dysfunction: reduced activities of electron transport chain enzymes and TCA cycle enzymes, dysregulated mitochondrial redox status, and disrupted mitochondrial membrane potential. Oligodendrocytes were more severely affected than astrocytes. These perturbations were corrected by HDAC inhibitor SAHA treatment.","method":"siRNA knockdown (ABCD1) in B12 and U87 cells; enzyme activity assays (ETC, TCA cycle); mitochondrial membrane potential measurement; ATP quantification; SAHA rescue","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined mitochondrial phenotype and pharmacological rescue; single lab, in vitro","pmids":["25393703"],"is_preprint":false},{"year":2019,"finding":"CRISPR/Cas9 knockout of Abcd1 alone in BV-2 microglial cells did not result in VLCFA accumulation, but combined Abcd1/Abcd2 double knockout caused VLCFA accumulation, lipid inclusions (similar to those in patient brain macrophages), increased cholesterol, and altered expression of microglial genes including Trem2, demonstrating functional redundancy between ABCD1 and ABCD2 specifically in microglia.","method":"CRISPR/Cas9 gene editing; VLCFA measurement; electron microscopy; cholesterol/lipid analysis; gene expression analysis","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR knockout with multiple orthogonal biochemical and ultrastructural readouts; genetic redundancy clearly established","pmids":["30769094"],"is_preprint":false},{"year":2021,"finding":"ABCD1 deficiency results in accumulation of saturated VLCFAs that cause ER stress in ALD fibroblasts, whereas monounsaturated VLCFAs do not. SCD1 (stearoyl-CoA desaturase-1) induction by chloroquine or LXR agonists shifted saturated to monounsaturated VLCFA, reducing lipid toxicity. Abcd1-/y mice treated with LXR agonist showed VLCFA reduction in ALD-relevant tissues, and CRISPR knockout of scd1 in zebrafish mimicked the ALD motor phenotype.","method":"Drug screen in zebrafish ALD model; CRISPR scd1 knockout in zebrafish; LXR agonist treatment of Abcd1-/y mice; VLCFA measurement; ER stress assays in ALD fibroblasts; pharmacological SCD1 inhibition","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal models (zebrafish, mouse, human fibroblasts), genetic rescue and knockout, mechanistic pathway established","pmids":["33690217"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structures of ABCD1 in six conformational states (four inward-facing, one outward-facing, plus additional states) revealed: (1) the substrate translocation pathway is formed by two transmembrane domains; (2) two NBDs form the ATP-binding/hydrolysis site; (3) C26:0-CoA substrate binds the TMDs and stimulates NBD ATPase activity; (4) W339 in TM5 is essential for substrate binding and ATP hydrolysis stimulation by substrate; (5) the unique C-terminal coiled-coil domain negatively modulates NBD ATPase activity; (6) in the outward-facing state, ATP binding pulls the two NBDs together and opens the TMDs to the peroxisomal lumen for substrate release.","method":"Cryo-electron microscopy (six structures); ATPase activity assays with substrate; site-directed mutagenesis (W339)","journal":"Signal transduction and targeted therapy","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution cryo-EM structures in multiple conformational states combined with mutagenesis and ATPase functional assays in a single rigorous study","pmids":["36810450"],"is_preprint":false},{"year":2023,"finding":"ABCD1 deficiency in X-ALD patient fibroblasts and Abcd1-deficient mouse CNS tissues leads to altered cholesterol homeostasis: accumulation of cholesterol esters (CE) containing both saturated VLCFA and mono/polyunsaturated (V)LCFA; increased SOAT1 expression and lipid droplet formation under cholesterol loading; compensatory upregulation of CE hydrolase NCEH1, cholesterol transporter ABCA1, and cholesterol efflux; elevated Apoe and Soat1 in mouse spinal cord.","method":"Lipidomics; gene expression analysis; lipid droplet staining; LXR agonist treatment; steroidogenesis assay in X-ALD fibroblasts; immunofluorescence for peroxisome-lipid droplet co-localization","journal":"Biomolecules","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical readouts in patient-derived cells and mouse tissue; single lab, no functional rescue experiment","pmids":["37759733"],"is_preprint":false}],"current_model":"ABCD1 encodes ALDP, a peroxisomal membrane half-ABC transporter that functions as a homodimer (predominant form) to transport CoA-activated very long-chain fatty acids (VLCFA, ≥C22) from the cytosol into the peroxisome for β-oxidation; cryo-EM structures reveal that C26:0-CoA binds the transmembrane domains (with W339 in TM5 being critical), stimulates NBD ATPase activity, and ATP hydrolysis drives conformational changes that open the substrate pathway to the peroxisomal lumen, while a unique C-terminal coiled-coil domain negatively modulates ATPase activity; ALDP deficiency causes VLCFA accumulation, ER stress, mitochondrial dysfunction, altered cholesterol homeostasis, and endothelial barrier disruption (via c-MYC downregulation), and its function partially overlaps with the related transporter ABCD2 (ALDRP), which can compensate when overexpressed."},"narrative":{"mechanistic_narrative":"ABCD1 encodes ALDP, a peroxisomal membrane half-transporter of the ATP-binding cassette superfamily that imports CoA-activated very long-chain fatty acids into the peroxisome for β-oxidation, acting as the rate-limiting gatekeeper of VLCFA homeostasis [PMID:8507690, PMID:8004093, PMID:10068511]. ALDP binds and hydrolyzes ATP in a Mg2+-dependent manner [PMID:12176987], and cryo-EM across multiple conformational states shows that C26:0-CoA binds the transmembrane domains—where W339 in TM5 is essential—stimulates NBD ATPase activity, and that ATP-driven NBD dimerization opens the substrate pathway to the peroxisomal lumen for release, with a unique C-terminal coiled-coil domain negatively modulating ATPase activity [PMID:36810450]. The functional unit is predominantly an ALDP homodimer, with the C-terminal ~87 residues being the principal interaction domain and also essential for protein stability, such that C-terminal missense and truncating mutations trigger rapid proteasomal degradation, including dominant-negative co-degradation of co-expressed wild-type protein [PMID:8892025, PMID:17609205, PMID:17542813]. ALDP function partially overlaps with the related transporter ABCD2 (ALDRP), which physically interacts with ALDP and, when overexpressed, restores peroxisomal β-oxidation and prevents both VLCFA accumulation and neurodegeneration in vivo, while combined ABCD1/ABCD2 loss produces synthetic severity [PMID:9809549, PMID:10196381, PMID:15489218, PMID:21209459, PMID:30769094]. ALDP deficiency causes VLCFA accumulation driving downstream pathology: saturated VLCFA-induced ER stress relievable by SCD1-mediated desaturation [PMID:33690217], mitochondrial dysfunction [PMID:25393703], inflammatory activation via NF-κB/AP-1/C/EBP [PMID:18723473], altered cholesterol ester homeostasis [PMID:37759733], and endothelial barrier disruption through c-MYC downregulation [PMID:26377633].","teleology":[{"year":1993,"claim":"Established the molecular identity of the disease gene, predicting that the unknown X-ALD defect lay in a peroxisomal ABC-family transporter rather than directly in fatty acid metabolism.","evidence":"Positional cloning with sequence homology to PMP70 and the ABC superfamily","pmids":["8507690"],"confidence":"Medium","gaps":["No direct demonstration of transport activity","Substrate not biochemically defined","Localization inferred from homology only"]},{"year":1994,"claim":"Confirmed ALDP is a bona fide peroxisomal membrane protein absent in patients, directly tying the gene product to the peroxisome and to disease.","evidence":"Monoclonal antibody Western blot, immunofluorescence and immunoelectron microscopy in patient and control cells","pmids":["8004093"],"confidence":"High","gaps":["Transport function not shown","Membrane topology not resolved","No substrate identified"]},{"year":1995,"claim":"Showed that disease mutations frequently abolish ALDP protein, implicating protein destabilization (not just catalytic loss) as a disease mechanism and assigning a stabilizing role to the C-terminus.","evidence":"Indirect immunofluorescence and mutation analysis across many patient fibroblast lines","pmids":["7668254","8651290","8892025"],"confidence":"Medium","gaps":["No genotype-phenotype correlation found","Degradation pathway not defined","Mechanism of C-terminal stabilization unknown"]},{"year":1999,"claim":"Defined ALDP abundance as the rate-limiting determinant of peroxisomal VLCFA β-oxidation, establishing its gatekeeper role.","evidence":"ALDP overexpression rescue of β-oxidation in transformed cells with co-reduced ACOX and ALDP","pmids":["10068511"],"confidence":"Medium","gaps":["Direct transport mechanism not measured","Does not distinguish import of substrate vs. enzyme anchoring"]},{"year":1999,"claim":"Demonstrated functional redundancy with the paralog ABCD2 and established that ALDP can self-associate, framing the peroxisomal ABC transporters as overlapping VLCFA handlers.","evidence":"ALDRP cDNA complementation and overexpression in patient fibroblasts with β-oxidation/VLCFA readouts; dimerization and VLCS activity assays; fenofibrate treatment of knockout mice","pmids":["9809549","10196381","10227685"],"confidence":"High","gaps":["In vivo predominant oligomeric state unresolved","Endogenous vs. forced-expression compensation not separated","Heterodimer significance unclear"]},{"year":2002,"claim":"Provided direct biochemical proof that ALDP binds and hydrolyzes ATP, confirming it as an active transporter rather than a passive anchor.","evidence":"Photoaffinity labeling with azido-ATP analogs and in vitro ATPase assays on native rat liver peroxisomes","pmids":["12176987"],"confidence":"High","gaps":["Substrate not coupled to ATPase in this study","Tyrosine phosphorylation function unknown","No vanadate trapping observed"]},{"year":2004,"claim":"Resolved the predominant in vivo oligomeric state as homomeric and validated ABCD1–ABCD2 redundancy genetically in whole animals.","evidence":"Native complex purification from mouse liver peroxisomes; transgenic ALDRP overexpression and ABCD1/ABCD2 double-knockout mouse phenotyping","pmids":["15276650","15489218"],"confidence":"High","gaps":["Native purification contradicts some in vitro heterodimer data","Tissue-specific oligomer composition not mapped"]},{"year":2007,"claim":"Mapped the dimerization interface to the C-terminus and linked C-terminal mutations to proteasomal, dominant-negative degradation, unifying protein-stability and oligomerization findings.","evidence":"Live-cell FRET with C-terminal deletion constructs, yeast two-hybrid; proteasome-inhibitor rescue of mutant ALDP and co-degradation assays","pmids":["17609205","17542813"],"confidence":"High","gaps":["Atomic structure of interface not resolved","Targeting signal between TM2-TM3 not precisely defined"]},{"year":2011,"claim":"Demonstrated a direct ALDP–ALDRP physical interaction with functional consequence, showing the paralogs are not merely redundant but can interact and that ABCD2 has distinct substrate preferences (DHA).","evidence":"Proximity ligation assay, co-IP, and dominant-negative inactive ALDRP-EGFP with substrate-specific β-oxidation assays","pmids":["21209459"],"confidence":"High","gaps":["Stoichiometry of heterocomplex unknown","Physiological role of heterodimer vs. homodimer unclear"]},{"year":2015,"claim":"Connected ALDP loss to cell-type-specific downstream pathology—endothelial barrier breakdown via c-MYC and mitochondrial dysfunction—extending the role beyond VLCFA transport.","evidence":"siRNA silencing in brain microvascular endothelial cells with MYC-knockdown epistasis; siRNA knockdown in oligodendrocyte/astrocyte lines with ETC/TCA enzyme and membrane-potential assays plus SAHA rescue","pmids":["26377633","25393703"],"confidence":"Medium","gaps":["Mechanistic link between VLCFA and c-MYC undefined","siRNA single-lab in vitro","Endothelial effect reported before VLCFA accumulation, mechanism unclear"]},{"year":2019,"claim":"Showed in microglia that single ABCD1 loss is buffered by ABCD2, refining the redundancy model to a cell-type-dependent threshold for VLCFA pathology.","evidence":"CRISPR/Cas9 single and double Abcd1/Abcd2 knockout in BV-2 microglia with VLCFA, lipid-inclusion, cholesterol and gene-expression readouts","pmids":["30769094"],"confidence":"High","gaps":["Mechanism of Trem2 dysregulation unresolved","Relevance to in vivo microglial disease not established"]},{"year":2021,"claim":"Identified saturated VLCFA species as the proximate cause of ER stress and validated SCD1-mediated desaturation as a corrective node, providing a mechanistic basis for lipotoxicity.","evidence":"Zebrafish drug screen and scd1 CRISPR knockout; LXR agonist treatment of Abcd1-/y mice; ER-stress assays in patient fibroblasts","pmids":["33690217"],"confidence":"High","gaps":["Molecular trigger linking VLCFA to UPR not defined","Therapeutic translation untested"]},{"year":2023,"claim":"Delivered the structural mechanism of substrate transport and uncovered altered cholesterol ester homeostasis as a downstream consequence, defining the transport cycle at near-atomic resolution.","evidence":"Cryo-EM in six conformational states with C26:0-CoA, W339 mutagenesis and substrate-stimulated ATPase assays; lipidomics, gene expression and lipid-droplet analysis in patient cells and mouse CNS","pmids":["36810450","37759733"],"confidence":"High","gaps":["Mechanism of C-terminal coiled-coil regulation not fully resolved","Cholesterol changes lack functional rescue","Link between transport cycle and in-cell pathology not directly bridged"]},{"year":null,"claim":"How VLCFA accumulation is mechanistically transduced into the diverse downstream phenotypes (ER stress, mitochondrial failure, inflammation, c-MYC loss, cholesterol dysregulation) and what determines the divergent clinical phenotypes remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying signaling pathway from VLCFA to phenotype identified","Genotype-phenotype determinants unknown","Tissue-specific compensation thresholds not fully mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[9,20]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,8,20]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[9,20]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[20]}],"localization":[{"term_id":"GO:0005777","term_label":"peroxisome","supporting_discovery_ids":[1,11]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[8,20,21]}],"complexes":[],"partners":["ABCD2","ABCD3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P33897","full_name":"ATP-binding cassette sub-family D member 1","aliases":["Adrenoleukodystrophy protein","ALDP"],"length_aa":745,"mass_kda":82.9,"function":"ATP-dependent transporter of the ATP-binding cassette (ABC) family involved in the transport of very long chain fatty acid (VLCFA)-CoA from the cytosol to the peroxisome lumen (PubMed:11248239, PubMed:15682271, PubMed:16946495, PubMed:18757502, PubMed:21145416, PubMed:23671276, PubMed:29397936, PubMed:33500543). Coupled to the ATP-dependent transporter activity also has a fatty acyl-CoA thioesterase activity (ACOT) and hydrolyzes VLCFA-CoA into VLCFA prior their ATP-dependent transport into peroxisomes, the ACOT activity is essential during this transport process (PubMed:29397936, PubMed:33500543). Thus, plays a role in regulation of VLCFAs and energy metabolism namely, in the degradation and biosynthesis of fatty acids by beta-oxidation, mitochondrial function and microsomal fatty acid elongation (PubMed:21145416, PubMed:23671276). Involved in several processes; namely, controls the active myelination phase by negatively regulating the microsomal fatty acid elongation activity and may also play a role in axon and myelin maintenance. Also controls the cellular response to oxidative stress by regulating mitochondrial functions such as mitochondrial oxidative phosphorylation and depolarization. And finally controls the inflammatory response by positively regulating peroxisomal beta-oxidation of VLCFAs (By similarity)","subcellular_location":"Peroxisome membrane; Mitochondrion membrane; Lysosome membrane; Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/P33897/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ABCD1","classification":"Not Classified","n_dependent_lines":49,"n_total_lines":1208,"dependency_fraction":0.04056291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ABCD1","total_profiled":1310},"omim":[{"mim_id":"618863","title":"RETINAL DYSTROPHY WITH LEUKODYSTROPHY; RDLKD","url":"https://www.omim.org/entry/618863"},{"mim_id":"616618","title":"ACYL-CoA-BINDING DOMAIN-CONTAINING PROTEIN 5; ACBD5","url":"https://www.omim.org/entry/616618"},{"mim_id":"614362","title":"ACYL-CoA SYNTHETASE, BUBBLEGUM FAMILY, MEMBER 1; ACSBG1","url":"https://www.omim.org/entry/614362"},{"mim_id":"603247","title":"SOLUTE CARRIER FAMILY 27 (FATTY ACID TRANSPORTER), MEMBER 2; SLC27A2","url":"https://www.omim.org/entry/603247"},{"mim_id":"603214","title":"ATP-BINDING CASSETTE, SUBFAMILY D, MEMBER 4; ABCD4","url":"https://www.omim.org/entry/603214"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ABCD1"},"hgnc":{"alias_symbol":["AMN","ALDP","adrenoleukodystrophy"],"prev_symbol":["ALD"]},"alphafold":{"accession":"P33897","domains":[{"cath_id":"-","chopping":"87-238_408-436","consensus_level":"medium","plddt":88.9138,"start":87,"end":436},{"cath_id":"3.40.50.300","chopping":"467-685","consensus_level":"high","plddt":91.6078,"start":467,"end":685},{"cath_id":"1.10.287","chopping":"240-355","consensus_level":"medium","plddt":86.0309,"start":240,"end":355}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P33897","model_url":"https://alphafold.ebi.ac.uk/files/AF-P33897-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P33897-F1-predicted_aligned_error_v6.png","plddt_mean":80.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ABCD1","jax_strain_url":"https://www.jax.org/strain/search?query=ABCD1"},"sequence":{"accession":"P33897","fasta_url":"https://rest.uniprot.org/uniprotkb/P33897.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P33897/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P33897"}},"corpus_meta":[{"pmid":"22889154","id":"PMC_22889154","title":"X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management.","date":"2012","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22889154","citation_count":419,"is_preprint":false},{"pmid":"17342190","id":"PMC_17342190","title":"X-linked adrenoleukodystrophy.","date":"2007","source":"Nature clinical practice. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17342190","citation_count":271,"is_preprint":false},{"pmid":"8004093","id":"PMC_8004093","title":"The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein.","date":"1994","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8004093","citation_count":230,"is_preprint":false},{"pmid":"11748843","id":"PMC_11748843","title":"ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations.","date":"2001","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/11748843","citation_count":229,"is_preprint":false},{"pmid":"22483867","id":"PMC_22483867","title":"X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22483867","citation_count":207,"is_preprint":false},{"pmid":"9809549","id":"PMC_9809549","title":"Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy.","date":"1998","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9809549","citation_count":201,"is_preprint":false},{"pmid":"27312864","id":"PMC_27312864","title":"Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history.","date":"2016","source":"Nature reviews. Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27312864","citation_count":198,"is_preprint":false},{"pmid":"24316281","id":"PMC_24316281","title":"Pathophysiology of X-linked adrenoleukodystrophy.","date":"2013","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/24316281","citation_count":167,"is_preprint":false},{"pmid":"15489218","id":"PMC_15489218","title":"Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy.","date":"2004","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15489218","citation_count":163,"is_preprint":false},{"pmid":"10227685","id":"PMC_10227685","title":"X-linked adrenoleukodystrophy: genes, mutations, and phenotypes.","date":"1999","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/10227685","citation_count":147,"is_preprint":false},{"pmid":"16949688","id":"PMC_16949688","title":"X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16949688","citation_count":147,"is_preprint":false},{"pmid":"31909500","id":"PMC_31909500","title":"X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies.","date":"2020","source":"International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31909500","citation_count":133,"is_preprint":false},{"pmid":"25115486","id":"PMC_25115486","title":"X-linked adrenoleukodystrophy: pathogenesis and treatment.","date":"2014","source":"Current neurology and neuroscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/25115486","citation_count":125,"is_preprint":false},{"pmid":"10196381","id":"PMC_10196381","title":"Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy.","date":"1999","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10196381","citation_count":122,"is_preprint":false},{"pmid":"9221959","id":"PMC_9221959","title":"X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.","date":"1997","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/9221959","citation_count":117,"is_preprint":false},{"pmid":"20626745","id":"PMC_20626745","title":"Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis.","date":"2010","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/20626745","citation_count":116,"is_preprint":false},{"pmid":"7668254","id":"PMC_7668254","title":"Altered expression of ALDP in X-linked adrenoleukodystrophy.","date":"1995","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7668254","citation_count":115,"is_preprint":false},{"pmid":"7825602","id":"PMC_7825602","title":"Spectrum of mutations in the gene encoding the adrenoleukodystrophy protein.","date":"1995","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7825602","citation_count":115,"is_preprint":false},{"pmid":"20626743","id":"PMC_20626743","title":"General aspects and neuropathology of X-linked adrenoleukodystrophy.","date":"2010","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/20626743","citation_count":110,"is_preprint":false},{"pmid":"39383458","id":"PMC_39383458","title":"Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy.","date":"2024","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39383458","citation_count":99,"is_preprint":false},{"pmid":"10088993","id":"PMC_10088993","title":"The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder.","date":"1999","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/10088993","citation_count":97,"is_preprint":false},{"pmid":"8651290","id":"PMC_8651290","title":"Mutational and protein analysis of patients and heterozygous women with X-linked adrenoleukodystrophy.","date":"1996","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8651290","citation_count":93,"is_preprint":false},{"pmid":"20626744","id":"PMC_20626744","title":"Biochemical aspects of X-linked adrenoleukodystrophy.","date":"2010","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/20626744","citation_count":86,"is_preprint":false},{"pmid":"31467997","id":"PMC_31467997","title":"Newborn Screening for X-Linked Adrenoleukodystrophy.","date":"2016","source":"International journal of neonatal screening","url":"https://pubmed.ncbi.nlm.nih.gov/31467997","citation_count":84,"is_preprint":false},{"pmid":"26377633","id":"PMC_26377633","title":"Brain endothelial dysfunction in cerebral adrenoleukodystrophy.","date":"2015","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26377633","citation_count":70,"is_preprint":false},{"pmid":"33409397","id":"PMC_33409397","title":"Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD).","date":"2021","source":"Translational gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/33409397","citation_count":66,"is_preprint":false},{"pmid":"39383459","id":"PMC_39383459","title":"Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy.","date":"2024","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39383459","citation_count":63,"is_preprint":false},{"pmid":"7468762","id":"PMC_7468762","title":"The testis in adreno-leukodystrophy.","date":"1981","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7468762","citation_count":62,"is_preprint":false},{"pmid":"26073123","id":"PMC_26073123","title":"Oxidative stress, mitochondrial and proteostasis malfunction in adrenoleukodystrophy: A paradigm for axonal degeneration.","date":"2015","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26073123","citation_count":62,"is_preprint":false},{"pmid":"8566952","id":"PMC_8566952","title":"Identification of mutations in the ALD-gene of 20 families with adrenoleukodystrophy/adrenomyeloneuropathy.","date":"1996","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8566952","citation_count":56,"is_preprint":false},{"pmid":"18723473","id":"PMC_18723473","title":"Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy.","date":"2008","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/18723473","citation_count":55,"is_preprint":false},{"pmid":"32364223","id":"PMC_32364223","title":"The Changing Face of Adrenoleukodystrophy.","date":"2020","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32364223","citation_count":53,"is_preprint":false},{"pmid":"29860501","id":"PMC_29860501","title":"Impaired plasticity of macrophages in X-linked adrenoleukodystrophy.","date":"2018","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29860501","citation_count":53,"is_preprint":false},{"pmid":"12176987","id":"PMC_12176987","title":"ATP binding/hydrolysis by and phosphorylation of peroxisomal ATP-binding cassette proteins PMP70 (ABCD3) and adrenoleukodystrophy protein (ABCD1).","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12176987","citation_count":51,"is_preprint":false},{"pmid":"17761426","id":"PMC_17761426","title":"Distribution and cellular localization of adrenoleukodystrophy protein in human tissues: implications for X-linked adrenoleukodystrophy.","date":"2007","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/17761426","citation_count":50,"is_preprint":false},{"pmid":"7593551","id":"PMC_7593551","title":"Tumor necrosis factor-alpha and X-linked adrenoleukodystrophy.","date":"1995","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/7593551","citation_count":50,"is_preprint":false},{"pmid":"36107226","id":"PMC_36107226","title":"Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy.","date":"2022","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36107226","citation_count":48,"is_preprint":false},{"pmid":"15167059","id":"PMC_15167059","title":"Progress in X-linked adrenoleukodystrophy.","date":"2004","source":"Current opinion in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15167059","citation_count":48,"is_preprint":false},{"pmid":"16305618","id":"PMC_16305618","title":"X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes.","date":"2005","source":"Pediatric transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/16305618","citation_count":46,"is_preprint":false},{"pmid":"32231001","id":"PMC_32231001","title":"Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32231001","citation_count":45,"is_preprint":false},{"pmid":"22112817","id":"PMC_22112817","title":"Adrenoleukodystrophy in female heterozygotes: underrecognized and undertreated.","date":"2011","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22112817","citation_count":45,"is_preprint":false},{"pmid":"35689610","id":"PMC_35689610","title":"Probiotic-derived nanoparticles inhibit ALD through intestinal miR194 suppression and subsequent FXR activation.","date":"2022","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/35689610","citation_count":42,"is_preprint":false},{"pmid":"17609205","id":"PMC_17609205","title":"Live cell FRET microscopy: homo- and heterodimerization of two human peroxisomal ABC transporters, the adrenoleukodystrophy protein (ALDP, ABCD1) and PMP70 (ABCD3).","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17609205","citation_count":42,"is_preprint":false},{"pmid":"35053399","id":"PMC_35053399","title":"Structure and Function of the ABCD1 Variant Database: 20 Years, 940 Pathogenic Variants, and 3400 Cases of Adrenoleukodystrophy.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35053399","citation_count":42,"is_preprint":false},{"pmid":"15276650","id":"PMC_15276650","title":"Mouse liver PMP70 and ALDP: homomeric interactions prevail in vivo.","date":"2004","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15276650","citation_count":42,"is_preprint":false},{"pmid":"25583114","id":"PMC_25583114","title":"Astrocytes and mitochondria from adrenoleukodystrophy protein (ABCD1)-deficient mice reveal that the adrenoleukodystrophy-associated very long-chain fatty acids target several cellular energy-dependent functions.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25583114","citation_count":42,"is_preprint":false},{"pmid":"7666063","id":"PMC_7666063","title":"Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy.","date":"1995","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/7666063","citation_count":39,"is_preprint":false},{"pmid":"16554262","id":"PMC_16554262","title":"Therapy of X-linked adrenoleukodystrophy.","date":"2006","source":"NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/16554262","citation_count":39,"is_preprint":false},{"pmid":"30769094","id":"PMC_30769094","title":"CRISPR/Cas9-mediated knockout of Abcd1 and Abcd2 genes in BV-2 cells: novel microglial models for X-linked Adrenoleukodystrophy.","date":"2019","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/30769094","citation_count":39,"is_preprint":false},{"pmid":"21700483","id":"PMC_21700483","title":"X-linked adrenoleukodystrophy: ABCD1 de novo mutations and mosaicism.","date":"2011","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21700483","citation_count":39,"is_preprint":false},{"pmid":"28632197","id":"PMC_28632197","title":"Toxic AGE (TAGE) Theory for the Pathophysiology of the Onset/Progression of NAFLD and ALD.","date":"2017","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/28632197","citation_count":38,"is_preprint":false},{"pmid":"21209459","id":"PMC_21209459","title":"Substrate specificity overlap and interaction between adrenoleukodystrophy protein (ALDP/ABCD1) and adrenoleukodystrophy-related protein (ALDRP/ABCD2).","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21209459","citation_count":37,"is_preprint":false},{"pmid":"9195223","id":"PMC_9195223","title":"Mutations in the adrenoleukodystrophy gene.","date":"1997","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/9195223","citation_count":36,"is_preprint":false},{"pmid":"27241966","id":"PMC_27241966","title":"Endocrine Dysfunction in X-Linked Adrenoleukodystrophy.","date":"2016","source":"Endocrinology and metabolism clinics of North America","url":"https://pubmed.ncbi.nlm.nih.gov/27241966","citation_count":36,"is_preprint":false},{"pmid":"25393703","id":"PMC_25393703","title":"ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.","date":"2015","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25393703","citation_count":35,"is_preprint":false},{"pmid":"33690217","id":"PMC_33690217","title":"Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33690217","citation_count":33,"is_preprint":false},{"pmid":"39256476","id":"PMC_39256476","title":"Lipidomic biomarkers in plasma correlate with disease severity in adrenoleukodystrophy.","date":"2024","source":"Communications medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39256476","citation_count":32,"is_preprint":false},{"pmid":"33047897","id":"PMC_33047897","title":"Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy.","date":"2020","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33047897","citation_count":32,"is_preprint":false},{"pmid":"8892025","id":"PMC_8892025","title":"ALDP expression in fibroblasts of patients with X-linked adrenoleukodystrophy.","date":"1996","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/8892025","citation_count":31,"is_preprint":false},{"pmid":"36256460","id":"PMC_36256460","title":"Sex-specific newborn screening for X-linked adrenoleukodystrophy.","date":"2022","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/36256460","citation_count":31,"is_preprint":false},{"pmid":"29136088","id":"PMC_29136088","title":"ABCD1 dysfunction alters white matter microvascular perfusion.","date":"2017","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29136088","citation_count":31,"is_preprint":false},{"pmid":"18759549","id":"PMC_18759549","title":"Therapy of X-linked adrenoleukodystrophy.","date":"2008","source":"Expert review of neurotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/18759549","citation_count":29,"is_preprint":false},{"pmid":"9553942","id":"PMC_9553942","title":"Clinical and genetic aspects of X-linked adrenoleukodystrophy.","date":"1998","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/9553942","citation_count":29,"is_preprint":false},{"pmid":"22280810","id":"PMC_22280810","title":"Preferential expression of mutant ABCD1 allele is common in adrenoleukodystrophy female carriers but unrelated to clinical symptoms.","date":"2012","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22280810","citation_count":29,"is_preprint":false},{"pmid":"39669199","id":"PMC_39669199","title":"Alcohol-related liver disease (ALD): current perspectives on pathogenesis, therapeutic strategies, and animal models.","date":"2024","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39669199","citation_count":28,"is_preprint":false},{"pmid":"17828604","id":"PMC_17828604","title":"Lack of adrenoleukodystrophy protein enhances oligodendrocyte disturbance and microglia activation in mice with combined Abcd1/Mag deficiency.","date":"2007","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/17828604","citation_count":28,"is_preprint":false},{"pmid":"24597975","id":"PMC_24597975","title":"Genotype-phenotype correlation of contiguous gene deletions of SLC6A8, BCAP31 and ABCD1.","date":"2014","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24597975","citation_count":28,"is_preprint":false},{"pmid":"17542813","id":"PMC_17542813","title":"Adrenoleukodystrophy: subcellular localization and degradation of adrenoleukodystrophy protein (ALDP/ABCD1) with naturally occurring missense mutations.","date":"2007","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17542813","citation_count":26,"is_preprint":false},{"pmid":"17125847","id":"PMC_17125847","title":"Immunopathogenesis of adrenoleukodystrophy: current understanding.","date":"2006","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/17125847","citation_count":26,"is_preprint":false},{"pmid":"26634687","id":"PMC_26634687","title":"An overview of the genetics, mechanisms and management of NAFLD and ALD.","date":"2015","source":"Clinical medicine (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26634687","citation_count":26,"is_preprint":false},{"pmid":"38969094","id":"PMC_38969094","title":"The role of gut microbiota, exosomes, and their interaction in the pathogenesis of ALD.","date":"2024","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/38969094","citation_count":25,"is_preprint":false},{"pmid":"16087056","id":"PMC_16087056","title":"ABCD1 gene mutations in Chinese patients with X-linked adrenoleukodystrophy.","date":"2005","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16087056","citation_count":25,"is_preprint":false},{"pmid":"38034003","id":"PMC_38034003","title":"X-linked adrenoleukodystrophy and primary adrenal insufficiency.","date":"2023","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/38034003","citation_count":23,"is_preprint":false},{"pmid":"8507690","id":"PMC_8507690","title":"Adrenoleukodystrophy gene: unexpected homology to a protein involved in peroxisome biogenesis.","date":"1993","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/8507690","citation_count":22,"is_preprint":false},{"pmid":"28288261","id":"PMC_28288261","title":"Antioxidant Capacity and Superoxide Dismutase Activity in Adrenoleukodystrophy.","date":"2017","source":"JAMA neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28288261","citation_count":21,"is_preprint":false},{"pmid":"8520725","id":"PMC_8520725","title":"Adrenoleukodystrophy: molecular genetics, pathology, and Lorenzo's oil.","date":"1995","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/8520725","citation_count":21,"is_preprint":false},{"pmid":"34560537","id":"PMC_34560537","title":"Management of adrenoleukodystrophy: From pre-clinical studies to the development of new therapies.","date":"2021","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/34560537","citation_count":20,"is_preprint":false},{"pmid":"29469952","id":"PMC_29469952","title":"Profiling and Imaging of Phospholipids in Brains of Abcd1-Deficient Mice.","date":"2018","source":"Lipids","url":"https://pubmed.ncbi.nlm.nih.gov/29469952","citation_count":20,"is_preprint":false},{"pmid":"22911730","id":"PMC_22911730","title":"Bezafibrate for X-linked adrenoleukodystrophy.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22911730","citation_count":20,"is_preprint":false},{"pmid":"11438993","id":"PMC_11438993","title":"Eight novel ABCD1 gene mutations and three polymorphisms in patients with X-linked adrenoleukodystrophy: The first polymorphism causing an amino acid exchange.","date":"2001","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/11438993","citation_count":20,"is_preprint":false},{"pmid":"34716609","id":"PMC_34716609","title":"ABCD1 and X-linked adrenoleukodystrophy: A disease with a markedly variable phenotype showing conserved neurobiology in animal models.","date":"2021","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/34716609","citation_count":19,"is_preprint":false},{"pmid":"36938877","id":"PMC_36938877","title":"Emerging targets for therapy in ALD: Lessons from NASH.","date":"2023","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/36938877","citation_count":19,"is_preprint":false},{"pmid":"17532287","id":"PMC_17532287","title":"[X-linked adrenoleukodystrophy].","date":"2007","source":"Annales d'endocrinologie","url":"https://pubmed.ncbi.nlm.nih.gov/17532287","citation_count":18,"is_preprint":false},{"pmid":"37979237","id":"PMC_37979237","title":"Newborn screening for adrenoleukodystrophy: International experiences and challenges.","date":"2023","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37979237","citation_count":18,"is_preprint":false},{"pmid":"34943935","id":"PMC_34943935","title":"Molecular Biomarkers for Adrenoleukodystrophy: An Unmet Need.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34943935","citation_count":18,"is_preprint":false},{"pmid":"29739804","id":"PMC_29739804","title":"Etiology and treatment of adrenoleukodystrophy: new insights from Drosophila.","date":"2018","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/29739804","citation_count":18,"is_preprint":false},{"pmid":"32359032","id":"PMC_32359032","title":"Vorinostat in the acute neuroinflammatory form of X-linked adrenoleukodystrophy.","date":"2020","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32359032","citation_count":18,"is_preprint":false},{"pmid":"21164268","id":"PMC_21164268","title":"Adrenoleukodystrophy.","date":"2010","source":"Endocrine development","url":"https://pubmed.ncbi.nlm.nih.gov/21164268","citation_count":17,"is_preprint":false},{"pmid":"34192790","id":"PMC_34192790","title":"Imaging in X-Linked Adrenoleukodystrophy.","date":"2021","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/34192790","citation_count":17,"is_preprint":false},{"pmid":"36810450","id":"PMC_36810450","title":"Structural insights into substrate recognition and translocation of human peroxisomal ABC transporter ALDP.","date":"2023","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36810450","citation_count":17,"is_preprint":false},{"pmid":"38832897","id":"PMC_38832897","title":"Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy.","date":"2024","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38832897","citation_count":16,"is_preprint":false},{"pmid":"10068511","id":"PMC_10068511","title":"Peroxisomal very long chain fatty acid beta-oxidation activity is determined by the level of adrenodeukodystrophy protein (ALDP) expression.","date":"1999","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10068511","citation_count":16,"is_preprint":false},{"pmid":"7551122","id":"PMC_7551122","title":"Adrenoleukodystrophy.","date":"1995","source":"Current opinion in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/7551122","citation_count":15,"is_preprint":false},{"pmid":"33274015","id":"PMC_33274015","title":"Deciphering the modifiers for phenotypic variability of X-linked adrenoleukodystrophy.","date":"2020","source":"World journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33274015","citation_count":15,"is_preprint":false},{"pmid":"11810273","id":"PMC_11810273","title":"Characterisation of two mutations in the ABCD1 gene leading to low levels of normal ALDP.","date":"2001","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11810273","citation_count":15,"is_preprint":false},{"pmid":"28493141","id":"PMC_28493141","title":"Therapeutic strategies in adrenoleukodystrophy.","date":"2017","source":"Wiener medizinische Wochenschrift (1946)","url":"https://pubmed.ncbi.nlm.nih.gov/28493141","citation_count":14,"is_preprint":false},{"pmid":"23300730","id":"PMC_23300730","title":"X-linked adrenoleukodystrophy: molecular and functional analysis of the ABCD1 gene in Argentinean patients.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23300730","citation_count":14,"is_preprint":false},{"pmid":"35983253","id":"PMC_35983253","title":"ABCD1 Gene Mutations: Mechanisms and Management of Adrenomyeloneuropathy.","date":"2022","source":"The application of clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35983253","citation_count":13,"is_preprint":false},{"pmid":"37759733","id":"PMC_37759733","title":"ABCD1 Transporter Deficiency Results in Altered Cholesterol Homeostasis.","date":"2023","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/37759733","citation_count":13,"is_preprint":false},{"pmid":"31133696","id":"PMC_31133696","title":"Association between APOE4 and biomarkers in cerebral adrenoleukodystrophy.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31133696","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48061,"output_tokens":5857,"usd":0.116019,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14649,"output_tokens":4234,"usd":0.089548,"stage2_stop_reason":"end_turn"},"total_usd":0.205567,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"Positional cloning identified the ALD gene, whose predicted protein (ALDP) shows significant homology to the 70-kDa peroxisomal membrane protein (PMP70) involved in peroxisome biogenesis and belongs to the ATP-binding cassette superfamily, suggesting it encodes a putative peroxisomal transporter involved in import or anchoring of VLCFA-CoA synthetase.\",\n      \"method\": \"Positional cloning; sequence homology analysis\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — positional cloning with functional inference; single study but gene identification confirmed by multiple subsequent labs\",\n      \"pmids\": [\"8507690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ALDP is a peroxisomal membrane protein: monoclonal antibodies detected a 75 kDa band absent in ALD patients, and immunofluorescence/immunoelectron microscopy localized ALDP to the peroxisomal membrane. Distinct immunofluorescence patterns were observed in Zellweger syndrome cell lines.\",\n      \"method\": \"Monoclonal antibody generation; immunofluorescence; immunoelectron microscopy; Western blot\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct subcellular localization by immunofluorescence and immunoelectron microscopy, replicated across multiple cell lines and confirmed in patient cells\",\n      \"pmids\": [\"8004093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"ALDP subcellular distribution and abundance examined in ALD patient fibroblasts: 69% of patients lacked punctate peroxisomal immunoreactivity; missense mutations could affect ALDP stability or localization; carboxy-terminal region has a function in stabilizing ALDP. No correlation between immunofluorescence pattern and clinical phenotype was found.\",\n      \"method\": \"Indirect immunofluorescence; mutation analysis in patient fibroblasts\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiments in patient-derived cells with mutation analysis; single lab but multiple patient samples\",\n      \"pmids\": [\"7668254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Analysis of 44 ALD kindreds showed that >50% of missense mutations led to complete absence of ALDP immunoreactivity, indicating mutations destabilize the protein; mutations concentrated in/near putative transmembrane segments 2–5, EAA-like motif, and ATP-binding domain. In heterozygous carriers from ALDP-negative kindreds, a mosaic pattern of ALDP-positive and -negative cells was confirmed by X-inactivation.\",\n      \"method\": \"SSCP/denaturing gradient gel electrophoresis; immunocytofluorescence; Western blot of fibroblasts and white blood cells\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — immunofluorescence and Western blot in patient cells with mutation mapping; single lab, multiple patients\",\n      \"pmids\": [\"8651290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Absence of truncated ALDP proteins in patients with nonsense/frameshift mutations in the carboxy terminus indicates the carboxy terminus is required for ALDP protein stability.\",\n      \"method\": \"Western blot; mutation analysis in patient fibroblasts\",\n      \"journal\": \"Journal of inherited metabolic disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Western blot in patient-derived fibroblasts correlated with mutation type; single lab\",\n      \"pmids\": [\"8892025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"4-Phenylbutyrate treatment of X-ALD patient cells and knockout mouse cells increased expression of the closely related peroxisomal protein ALDRP (ABCD2), decreased VLCFA levels, and increased VLCFA beta-oxidation. ALDRP cDNA complementation of X-ALD fibroblasts corrected the biochemical defect, demonstrating functional redundancy between ALDP and ALDRP.\",\n      \"method\": \"cDNA complementation in X-ALD fibroblasts; VLCFA beta-oxidation assay; ALDRP expression analysis; dietary treatment of X-ALD knockout mice\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — complementation assay with functional beta-oxidation readout in patient cells, plus in vivo mouse data; multiple orthogonal methods\",\n      \"pmids\": [\"9809549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ALDP forms homodimers with itself and heterodimers with other peroxisomal ABC proteins (ALDRP, PMP70). cDNA complementation studies suggest overlapping functions among peroxisomal ABC proteins. There are at least two peroxisomal VLCFA-CoA synthetase (VLCS) activities, one ALDP-dependent and one ALDP-independent.\",\n      \"method\": \"Protein dimerization assays (in vitro); cDNA complementation; VLCS activity assays\",\n      \"journal\": \"Neurochemical research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro dimerization and functional complementation; single lab\",\n      \"pmids\": [\"10227685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Overexpression of ALDRP (ABCD2) in X-ALD patient fibroblasts restored impaired peroxisomal beta-oxidation and prevented VLCFA accumulation, functionally replacing ALDP. Dietary fenofibrate treatment of ALDP-deficient mice stimulated ALDRP and PMP70 expression and corrected the peroxisomal beta-oxidation defect in liver.\",\n      \"method\": \"Transient and stable cDNA overexpression in X-ALD fibroblasts; peroxisomal beta-oxidation assay; VLCFA measurement; dietary treatment of knockout mice; immunofluorescence\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — functional restoration by complementation in patient cells confirmed by beta-oxidation assay and VLCFA measurement, plus in vivo mouse confirmation\",\n      \"pmids\": [\"10196381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ALDP expression level is a fundamental determinant of peroxisomal VLCFA beta-oxidation: ALDP overexpression alone restored peroxisomal VLCFA beta-oxidation in SV40T-transformed cells where both acyl-CoA oxidase and ALDP were reduced, demonstrating ALDP acts as a 'gatekeeper' for VLCFA homeostasis.\",\n      \"method\": \"ALDP overexpression in SV40T-transformed cells; peroxisomal beta-oxidation assay; Western blot\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro functional assay with overexpression rescue; single lab\",\n      \"pmids\": [\"10068511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ALDP (and PMP70/ABCD3) bind and hydrolyze ATP: photoaffinity labeling of rat liver peroxisomes showed both proteins bind 8-azido-ATP; Mg2+ promoted ATP hydrolysis to ADP with subsequent ADP dissociation. Both ALDP and PMP70 were also phosphorylated at tyrosine residue(s). Vanadate-induced nucleotide trapping was not observed.\",\n      \"method\": \"Photoaffinity labeling with 8-azido-[α-32P]ATP and 8-azido-[γ-32P]ATP; co-immunoprecipitation; in vitro ATPase assay using rat liver peroxisomes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct biochemical demonstration of ATP binding and hydrolysis by ALDP in native peroxisomes with multiple nucleotide analogs and Mg2+ dependency\",\n      \"pmids\": [\"12176987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In vivo genetic epistasis in ALD-knockout mice: overexpression of ALDRP (ABCD2) prevented both VLCFA accumulation and neurodegenerative features in ALD(-/-) mice. Double knockout (ALD/ALDRP) mice showed earlier onset and more severe disease including inflammatory features compared to ALD single mutants. This demonstrates functional redundancy/overlap between ABCD1 and ABCD2 in vivo.\",\n      \"method\": \"Transgenic mouse overexpression; double knockout mouse model; VLCFA measurement; histopathology; behavioral analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with rescue and synthetic severity phenotypes in vivo, replicated across multiple mouse lines\",\n      \"pmids\": [\"15489218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Mouse liver ALDP and PMP70 predominantly form homomeric complexes in vivo: two-step purification and preparative immunoprecipitation of mouse liver peroxisomes showed no evidence of ALDP/PMP70 heterodimers or accessory proteins under normal expression conditions.\",\n      \"method\": \"Protein complex purification from mouse liver peroxisomes; preparative immunoprecipitation; biochemical characterization\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical purification from native tissue; single lab; contradicts some in vitro studies\",\n      \"pmids\": [\"15276650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ALDP forms homodimers and ALDP/PMP70 heterodimers in living cells as demonstrated by FRET microscopy. ALDP homodimers predominate. The last 87 C-terminal amino acids are the most important domain mediating these interactions, and the N-terminal transmembrane region provides additional stabilization of ALDP homodimers.\",\n      \"method\": \"Live-cell FRET microscopy; C-terminal deletion constructs; yeast two-hybrid; immunoprecipitation; statistical analysis (PDSA and KS tests)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vivo FRET in intact living cells with domain-deletion mutagenesis; multiple orthogonal methods; rigorous statistical validation\",\n      \"pmids\": [\"17609205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Missense mutations in the C-terminal half of ALDP (S606L, R617H, H667D) cause rapid proteasomal degradation; a proteasome inhibitor restored mutant ALDP expression. Wild-type ALDP co-expressed with H667D mutant also disappeared, suggesting dominant-negative degradation after dimerization. The region between transmembrane domains 2 and 3 (e.g., Y174C mutation) is required for peroxisomal targeting of ALDP.\",\n      \"method\": \"Expression of mutant ALDP in X-ALD fibroblasts and CHO cells; proteasome inhibitor treatment; immunofluorescence; Western blot\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — proteasome inhibitor rescue of mutant protein, dominant-negative co-degradation, and localization mutant; multiple orthogonal methods in single study\",\n      \"pmids\": [\"17542813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"siRNA-mediated silencing of Abcd1 (and Abcd2) in mouse primary astrocytes caused VLCFA accumulation and triggered an inflammatory response involving NF-κB, AP-1, and C/EBP transcription factors, including induction of iNOS and inflammatory cytokines. Correction of the metabolic defect with monoenoic fatty acids reduced the inflammatory response, directly linking VLCFA accumulation to inflammation.\",\n      \"method\": \"siRNA knockdown in primary mouse astrocytes; VLCFA measurement; inflammatory gene expression; transcription factor analysis; monoenoic fatty acid rescue\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with specific inflammatory phenotype and metabolic rescue; single lab, in vitro\",\n      \"pmids\": [\"18723473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ALDRP (ABCD2) and ALDP (ABCD1) physically interact: proximity ligation assay and co-immunoprecipitation demonstrated a direct protein-protein interaction between ALDRP and ALDP. Inactive ALDRP-EGFP exerted a trans-dominant-negative effect on ALDP function, reducing beta-oxidation of C26:0 and C24:0. ALDRP overexpression reduces saturated VLCFA (redundant with ALDP) and specifically promotes DHA (C22:6n-3) metabolism.\",\n      \"method\": \"Proximity ligation assay; co-immunoprecipitation; inducible expression of wild-type and mutant ALDRP-EGFP; fatty acid content analysis in phospholipids; beta-oxidation assays for C26:0, C24:0, and DHA\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — physical interaction confirmed by two orthogonal methods (PLA and Co-IP); functional consequence demonstrated by dominant-negative and dose-dependent beta-oxidation assays\",\n      \"pmids\": [\"21209459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ABCD1 deficiency in brain endothelial cells (via siRNA silencing) caused upregulation of adhesion molecules (ICAM1) and downregulation of tight junction proteins (CLDN5) before VLCFA accumulation, mediated through downregulation of the transcription factor c-MYC. MYC silencing mimicked the effects of ABCD1 silencing on CLDN5 and ICAM1 without affecting ABCD1 protein levels, placing c-MYC downstream of ABCD1 but upstream of endothelial barrier function.\",\n      \"method\": \"siRNA silencing of ABCD1 in human brain microvascular endothelial cells; PCR array; Western blot; MYC silencing; monocyte adhesion and transmigration assays\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established by MYC knockdown mimicking ABCD1 knockdown phenotype; single lab, in vitro\",\n      \"pmids\": [\"26377633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ABCD1 silencing in oligodendrocyte (B12) and astrocyte (U87) cells caused mitochondrial dysfunction: reduced activities of electron transport chain enzymes and TCA cycle enzymes, dysregulated mitochondrial redox status, and disrupted mitochondrial membrane potential. Oligodendrocytes were more severely affected than astrocytes. These perturbations were corrected by HDAC inhibitor SAHA treatment.\",\n      \"method\": \"siRNA knockdown (ABCD1) in B12 and U87 cells; enzyme activity assays (ETC, TCA cycle); mitochondrial membrane potential measurement; ATP quantification; SAHA rescue\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined mitochondrial phenotype and pharmacological rescue; single lab, in vitro\",\n      \"pmids\": [\"25393703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CRISPR/Cas9 knockout of Abcd1 alone in BV-2 microglial cells did not result in VLCFA accumulation, but combined Abcd1/Abcd2 double knockout caused VLCFA accumulation, lipid inclusions (similar to those in patient brain macrophages), increased cholesterol, and altered expression of microglial genes including Trem2, demonstrating functional redundancy between ABCD1 and ABCD2 specifically in microglia.\",\n      \"method\": \"CRISPR/Cas9 gene editing; VLCFA measurement; electron microscopy; cholesterol/lipid analysis; gene expression analysis\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR knockout with multiple orthogonal biochemical and ultrastructural readouts; genetic redundancy clearly established\",\n      \"pmids\": [\"30769094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ABCD1 deficiency results in accumulation of saturated VLCFAs that cause ER stress in ALD fibroblasts, whereas monounsaturated VLCFAs do not. SCD1 (stearoyl-CoA desaturase-1) induction by chloroquine or LXR agonists shifted saturated to monounsaturated VLCFA, reducing lipid toxicity. Abcd1-/y mice treated with LXR agonist showed VLCFA reduction in ALD-relevant tissues, and CRISPR knockout of scd1 in zebrafish mimicked the ALD motor phenotype.\",\n      \"method\": \"Drug screen in zebrafish ALD model; CRISPR scd1 knockout in zebrafish; LXR agonist treatment of Abcd1-/y mice; VLCFA measurement; ER stress assays in ALD fibroblasts; pharmacological SCD1 inhibition\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal models (zebrafish, mouse, human fibroblasts), genetic rescue and knockout, mechanistic pathway established\",\n      \"pmids\": [\"33690217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structures of ABCD1 in six conformational states (four inward-facing, one outward-facing, plus additional states) revealed: (1) the substrate translocation pathway is formed by two transmembrane domains; (2) two NBDs form the ATP-binding/hydrolysis site; (3) C26:0-CoA substrate binds the TMDs and stimulates NBD ATPase activity; (4) W339 in TM5 is essential for substrate binding and ATP hydrolysis stimulation by substrate; (5) the unique C-terminal coiled-coil domain negatively modulates NBD ATPase activity; (6) in the outward-facing state, ATP binding pulls the two NBDs together and opens the TMDs to the peroxisomal lumen for substrate release.\",\n      \"method\": \"Cryo-electron microscopy (six structures); ATPase activity assays with substrate; site-directed mutagenesis (W339)\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution cryo-EM structures in multiple conformational states combined with mutagenesis and ATPase functional assays in a single rigorous study\",\n      \"pmids\": [\"36810450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ABCD1 deficiency in X-ALD patient fibroblasts and Abcd1-deficient mouse CNS tissues leads to altered cholesterol homeostasis: accumulation of cholesterol esters (CE) containing both saturated VLCFA and mono/polyunsaturated (V)LCFA; increased SOAT1 expression and lipid droplet formation under cholesterol loading; compensatory upregulation of CE hydrolase NCEH1, cholesterol transporter ABCA1, and cholesterol efflux; elevated Apoe and Soat1 in mouse spinal cord.\",\n      \"method\": \"Lipidomics; gene expression analysis; lipid droplet staining; LXR agonist treatment; steroidogenesis assay in X-ALD fibroblasts; immunofluorescence for peroxisome-lipid droplet co-localization\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical readouts in patient-derived cells and mouse tissue; single lab, no functional rescue experiment\",\n      \"pmids\": [\"37759733\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ABCD1 encodes ALDP, a peroxisomal membrane half-ABC transporter that functions as a homodimer (predominant form) to transport CoA-activated very long-chain fatty acids (VLCFA, ≥C22) from the cytosol into the peroxisome for β-oxidation; cryo-EM structures reveal that C26:0-CoA binds the transmembrane domains (with W339 in TM5 being critical), stimulates NBD ATPase activity, and ATP hydrolysis drives conformational changes that open the substrate pathway to the peroxisomal lumen, while a unique C-terminal coiled-coil domain negatively modulates ATPase activity; ALDP deficiency causes VLCFA accumulation, ER stress, mitochondrial dysfunction, altered cholesterol homeostasis, and endothelial barrier disruption (via c-MYC downregulation), and its function partially overlaps with the related transporter ABCD2 (ALDRP), which can compensate when overexpressed.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ABCD1 encodes ALDP, a peroxisomal membrane half-transporter of the ATP-binding cassette superfamily that imports CoA-activated very long-chain fatty acids into the peroxisome for β-oxidation, acting as the rate-limiting gatekeeper of VLCFA homeostasis [#0, #1, #8]. ALDP binds and hydrolyzes ATP in a Mg2+-dependent manner [#9], and cryo-EM across multiple conformational states shows that C26:0-CoA binds the transmembrane domains—where W339 in TM5 is essential—stimulates NBD ATPase activity, and that ATP-driven NBD dimerization opens the substrate pathway to the peroxisomal lumen for release, with a unique C-terminal coiled-coil domain negatively modulating ATPase activity [#20]. The functional unit is predominantly an ALDP homodimer, with the C-terminal ~87 residues being the principal interaction domain and also essential for protein stability, such that C-terminal missense and truncating mutations trigger rapid proteasomal degradation, including dominant-negative co-degradation of co-expressed wild-type protein [#4, #12, #13]. ALDP function partially overlaps with the related transporter ABCD2 (ALDRP), which physically interacts with ALDP and, when overexpressed, restores peroxisomal β-oxidation and prevents both VLCFA accumulation and neurodegeneration in vivo, while combined ABCD1/ABCD2 loss produces synthetic severity [#5, #7, #10, #15, #18]. ALDP deficiency causes VLCFA accumulation driving downstream pathology: saturated VLCFA-induced ER stress relievable by SCD1-mediated desaturation [#19], mitochondrial dysfunction [#17], inflammatory activation via NF-κB/AP-1/C/EBP [#14], altered cholesterol ester homeostasis [#21], and endothelial barrier disruption through c-MYC downregulation [#16].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established the molecular identity of the disease gene, predicting that the unknown X-ALD defect lay in a peroxisomal ABC-family transporter rather than directly in fatty acid metabolism.\",\n      \"evidence\": \"Positional cloning with sequence homology to PMP70 and the ABC superfamily\",\n      \"pmids\": [\"8507690\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct demonstration of transport activity\", \"Substrate not biochemically defined\", \"Localization inferred from homology only\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Confirmed ALDP is a bona fide peroxisomal membrane protein absent in patients, directly tying the gene product to the peroxisome and to disease.\",\n      \"evidence\": \"Monoclonal antibody Western blot, immunofluorescence and immunoelectron microscopy in patient and control cells\",\n      \"pmids\": [\"8004093\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transport function not shown\", \"Membrane topology not resolved\", \"No substrate identified\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Showed that disease mutations frequently abolish ALDP protein, implicating protein destabilization (not just catalytic loss) as a disease mechanism and assigning a stabilizing role to the C-terminus.\",\n      \"evidence\": \"Indirect immunofluorescence and mutation analysis across many patient fibroblast lines\",\n      \"pmids\": [\"7668254\", \"8651290\", \"8892025\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genotype-phenotype correlation found\", \"Degradation pathway not defined\", \"Mechanism of C-terminal stabilization unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined ALDP abundance as the rate-limiting determinant of peroxisomal VLCFA β-oxidation, establishing its gatekeeper role.\",\n      \"evidence\": \"ALDP overexpression rescue of β-oxidation in transformed cells with co-reduced ACOX and ALDP\",\n      \"pmids\": [\"10068511\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transport mechanism not measured\", \"Does not distinguish import of substrate vs. enzyme anchoring\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrated functional redundancy with the paralog ABCD2 and established that ALDP can self-associate, framing the peroxisomal ABC transporters as overlapping VLCFA handlers.\",\n      \"evidence\": \"ALDRP cDNA complementation and overexpression in patient fibroblasts with β-oxidation/VLCFA readouts; dimerization and VLCS activity assays; fenofibrate treatment of knockout mice\",\n      \"pmids\": [\"9809549\", \"10196381\", \"10227685\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo predominant oligomeric state unresolved\", \"Endogenous vs. forced-expression compensation not separated\", \"Heterodimer significance unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Provided direct biochemical proof that ALDP binds and hydrolyzes ATP, confirming it as an active transporter rather than a passive anchor.\",\n      \"evidence\": \"Photoaffinity labeling with azido-ATP analogs and in vitro ATPase assays on native rat liver peroxisomes\",\n      \"pmids\": [\"12176987\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate not coupled to ATPase in this study\", \"Tyrosine phosphorylation function unknown\", \"No vanadate trapping observed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Resolved the predominant in vivo oligomeric state as homomeric and validated ABCD1–ABCD2 redundancy genetically in whole animals.\",\n      \"evidence\": \"Native complex purification from mouse liver peroxisomes; transgenic ALDRP overexpression and ABCD1/ABCD2 double-knockout mouse phenotyping\",\n      \"pmids\": [\"15276650\", \"15489218\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Native purification contradicts some in vitro heterodimer data\", \"Tissue-specific oligomer composition not mapped\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Mapped the dimerization interface to the C-terminus and linked C-terminal mutations to proteasomal, dominant-negative degradation, unifying protein-stability and oligomerization findings.\",\n      \"evidence\": \"Live-cell FRET with C-terminal deletion constructs, yeast two-hybrid; proteasome-inhibitor rescue of mutant ALDP and co-degradation assays\",\n      \"pmids\": [\"17609205\", \"17542813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic structure of interface not resolved\", \"Targeting signal between TM2-TM3 not precisely defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated a direct ALDP–ALDRP physical interaction with functional consequence, showing the paralogs are not merely redundant but can interact and that ABCD2 has distinct substrate preferences (DHA).\",\n      \"evidence\": \"Proximity ligation assay, co-IP, and dominant-negative inactive ALDRP-EGFP with substrate-specific β-oxidation assays\",\n      \"pmids\": [\"21209459\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of heterocomplex unknown\", \"Physiological role of heterodimer vs. homodimer unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected ALDP loss to cell-type-specific downstream pathology—endothelial barrier breakdown via c-MYC and mitochondrial dysfunction—extending the role beyond VLCFA transport.\",\n      \"evidence\": \"siRNA silencing in brain microvascular endothelial cells with MYC-knockdown epistasis; siRNA knockdown in oligodendrocyte/astrocyte lines with ETC/TCA enzyme and membrane-potential assays plus SAHA rescue\",\n      \"pmids\": [\"26377633\", \"25393703\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link between VLCFA and c-MYC undefined\", \"siRNA single-lab in vitro\", \"Endothelial effect reported before VLCFA accumulation, mechanism unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed in microglia that single ABCD1 loss is buffered by ABCD2, refining the redundancy model to a cell-type-dependent threshold for VLCFA pathology.\",\n      \"evidence\": \"CRISPR/Cas9 single and double Abcd1/Abcd2 knockout in BV-2 microglia with VLCFA, lipid-inclusion, cholesterol and gene-expression readouts\",\n      \"pmids\": [\"30769094\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of Trem2 dysregulation unresolved\", \"Relevance to in vivo microglial disease not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified saturated VLCFA species as the proximate cause of ER stress and validated SCD1-mediated desaturation as a corrective node, providing a mechanistic basis for lipotoxicity.\",\n      \"evidence\": \"Zebrafish drug screen and scd1 CRISPR knockout; LXR agonist treatment of Abcd1-/y mice; ER-stress assays in patient fibroblasts\",\n      \"pmids\": [\"33690217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular trigger linking VLCFA to UPR not defined\", \"Therapeutic translation untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Delivered the structural mechanism of substrate transport and uncovered altered cholesterol ester homeostasis as a downstream consequence, defining the transport cycle at near-atomic resolution.\",\n      \"evidence\": \"Cryo-EM in six conformational states with C26:0-CoA, W339 mutagenesis and substrate-stimulated ATPase assays; lipidomics, gene expression and lipid-droplet analysis in patient cells and mouse CNS\",\n      \"pmids\": [\"36810450\", \"37759733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of C-terminal coiled-coil regulation not fully resolved\", \"Cholesterol changes lack functional rescue\", \"Link between transport cycle and in-cell pathology not directly bridged\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How VLCFA accumulation is mechanistically transduced into the diverse downstream phenotypes (ER stress, mitochondrial failure, inflammation, c-MYC loss, cholesterol dysregulation) and what determines the divergent clinical phenotypes remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying signaling pathway from VLCFA to phenotype identified\", \"Genotype-phenotype determinants unknown\", \"Tissue-specific compensation thresholds not fully mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [9, 20]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 8, 20]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [9, 20]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005777\", \"supporting_discovery_ids\": [1, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [8, 20, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ABCD2\", \"ABCD3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}